Format

Send to

Choose Destination
Oncotarget. 2017 Aug 2;8(39):66112-66116. doi: 10.18632/oncotarget.19805. eCollection 2017 Sep 12.

177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer.

Author information

1
Center of Tobacco Control Research, Odense, Denmark.
2
Docrates Cancer Center, Helsinki, Finland.
3
Department of Nuclear Medicine, Innsbruck University Hospital, Innsbruck, Austria.

Abstract

Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. 177Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report describes a patient with a third recurrence in lymph nodes. The recurrence was treated with 177Lu-PSMA radioligand therapy instead of chemotherapy with docetaxel. The effect was in part evaluated relative to that of two established salvage treatments. Prior salvage radiotherapy and abiraterone of the first and second recurrence in lymph nodes had given only a partial reduction of PSA. Nevertheless within five months of follow-up, 177Lu-PSMA radioligand therapy of the third recurrence in lymph nodes reduced PSA for a period to unmeasurable levels. 177Lu-PSMA radioligand therapy gave only mild adverse effects. In conclusion, for a patient with lymph node metastatic prostate cancer, 177Lu-PSMA-617 radioligand therapy had an attractive therapeutic profile. A follow-up study of similar patients is being planned.

KEYWORDS:

abiraterone; cross-over study; external beam radiotherapy; lutetium radiolabled prostate membrane specific antigen radioligand therapy; metastatic prostate cancer

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center